Fecal microbiota transplantation for Clostridium difficile infection: Benefits and barriers

Current Opinion in Gastroenterology

Volumn 30, Issue 1, 2014, Pages 47-53

  Lo Vecchio, Andrea ^a,b   Cohen, Mitchell B ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection; Clostridium difficile recurrence; fecal microbiota transplantation; microbiota; microflora

Indexed keywords

FIDAXOMICIN; LOPERAMIDE; MACROGOL; MONOCLONAL ANTIBODY; PROTON PUMP INHIBITOR; VANCOMYCIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BLOOD AUTOTRANSFUSION; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DONOR; ERUCTATION; FECAL MICROBIOTA TRANSPLANTATION; FECES; FECES MICROFLORA; FOLLOW UP; HUMAN; MICROFLORA; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; RECURRENT DISEASE; REVIEW; TRANSPLANTATION; VOMITING;

ENTEROCOLITIS, PSEUDOMEMBRANOUS; EVIDENCE-BASED MEDICINE; FECES; HUMANS; INTESTINES; MICROBIOTA; RECURRENCE; TISSUE TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84890426014     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000023     Document Type: Review

References (39)

1. Ananthakrishnan AN. Clostridium difficile infection: Epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8:17-26.
2. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266-1270.
3. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009; 33:S42-S45.
4. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-549.
5. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
6. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46:1489-1492.
7. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiotia transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079-1087. This study, performed in five centers in the US, is the only one reporting long-term efficacy and side effects of FMT in patients with recurrent CDI. Limitations are due to the retrospective survey design.
8. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15:285-289.
9. Bauer M, Notermans D, Van Benthem B, et al. ECDIS Study Group. Clostridium difficile infection in Europe: A hospital-based survey. Lancet 2011; 377:63-73.
10. Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in the treatment of C. difficile infection. Am J Gastroenterol 2013; 108:177-185. An extensive point of view of one of the major experts on this issue, including the role of microbiota in different human diseases including CDI, the rationale and details of FMT and highlights on patient management and personal experience.
11. Buccigrossi V, Nicastro E, Guarino A. Functions of intestinal microflora in children. Curr Opin Gastroenterol 2013; 29:31-38. A recent review focused on the composition of intestinal microbiota, its functional relationship with the host, and the role of abnormal microflora in chronic diseases.
12. Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol 2008; 16:107-114.
13. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol 2011; 14:82-91. 14.
14. Vedantam G, Clark A, Chu M, et al. Clostridium difficile infection: Toxins and nontoxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 2012; 3:121-134. An excellent review of genetic, nontoxin virulence factors, and host-cell biology associated with C. difficile pathogenesis.
15. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. Bacteriol J 2010; 192:4983-4990.
16. He X, Tian Y, Guo L, et al. Oral-derived bacterial flora defends its domain by recognizing and killing intruders: A molecular analysis using Escherichia coli as a model intestinal bacterium. Microb Ecol 2010; 60:655-664.
17. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: Colonisation with nontoxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009; 33:S46-50.
18. Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002; 186:1781-1789.
19. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435-438.
20. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012; 8:e1002995. This study reports a series of experiments in a mouse model of CDI that elegantly clarify the pathophysiology of C. difficile infection and the rationale of FMT use.
21. Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article. Faecal transplantation therapy for gastrointestinal disease. Alim Pharmacol Ther 2011; 34:409-415.
22. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacterio-therapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
23. Guo B, Hartsall C, Louie T, et al. Systematic review: Fecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35:865-875. 24.
24. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: Systematic review and meta-analysis. Am J Gastroenterol 2013; 108:500-508. A recent and well-conducted meta-analysis of noncontrolled trials on FMT in patients with recurrent CDI. Authors reported an efficacy of about 90% with relevant consistency among studies. In addition, they analyzed factors that may influence the efficacy, such as route of administration, donors' characteristics or quality of included studies.
25. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-415. The only RCT studying the efficacy of FMT in recurrent CDI published till now. The study (not blinded) was interrupted for evident benefits in the intervention arm.
26. Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010; 44:551-561.
27. Khoruts A, Dicksved J, Jansson JK, SadowskyMJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44:354-360.
28. Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: 'first-line' treatment for severe clostridium difficile infection J Clin Gastroenterol 2011; 45:655-657.
29. Agito MD, Atreja A, Rizk MK. Fecal microbiota transplantation for recurrent C. difficile infection: Ready for prime time Cleve Clin J Med 2013; 80:101-108. Practical, simple and clear review on indications and administration options for patients with CDI.
30. Bakken JS, Borody T, Brandt LJ, et al. and the Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-1049.
31. Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: A proposed treatment protocol. Pediatrics 2010; 126:e239-e242.
32. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:761-767. This retrospective study reported the experience of a referral center for FMT where a frozen, ready-to-use donor fecal material was obtained from healthy volunteers. Authors reported no significant change in efficacy between selected donors and 'standard' stored material.
33. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10:735-742.
34. Anathaswamy A. Faecal transplant eases symptoms of Parkinson's. New Scientist 2011; 2796:8-9.
35. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143:913-916; e7. Randomized trial studying the effects of infusing intestinal microbiota from lean donors to recipients with metabolic syndrome.
36. Vrieze A, de Groot PF, Kootte RS, et al. Fecal transplant: A safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease Best Pract Res Clin Gastroenterol 2013; 27:127-137. A recent review (mainly based on case-reports) that showed the available evidence regarding the involvement of intestinal microbiota and autoimmune diseases.
37. Lo Vecchio A, Zacur GM. Clostridium difficile infection: An update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28:1-9.
38. Jiang ZD, Hoang LN, Lasco TM, et al. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis 2013; 56:1059-1060. This is a recent survey performed in 264 specialists in gastroenterology and infectious diseases. Eighty-nine percent of gastroenterologists and 81% of infectious disease specialists would refer their patients to FMT.
39. Zipursky JS, Sidorsky TI, Freedman CA, et al. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012; 55:1652-1658. This survey explores patients' attitudes toward the use of FMT. Eighty-five percent of patients chose to receive FMT and this rate was reduced to 81% after explanation of the procedure. Acceptance was higher if recommended by physician and in case of administration in 'pills'. More women and elderly people defined the procedure as unappealing.